Monica Di Luca

Articles in Scholarly Journals [Incomplete List]

  1. Evidence of White Matter Changes on Diffusion Tensor Imaging in Frontotemporal Dementia
    Archives of Neurology, vol. 64, no. 2, pp. 246–251, 2007
  2. Dual role of CaMKII-dependent SAP97 phosphorylation in mediating trafficking and insertion of NMDA receptor subunit NR2A
    Journal of Neurochemistry, vol. 100, no. 4, pp. 1032–1046, 2007
  3. Latent profile analysis in frontotemporal lobar degeneration and related disorders: clinical presentation and SPECT functional correlates
    BMC Neurology, vol. 7, no. 1, p. 9, 2007
  4. The effect of APOE genotype on clinical phenotype in Alzheimer disease
    Neurology, vol. 68, no. 8, pp. 624–624, 2007
  5. Neonatal Exposure to Brominated Flame Retardant BDE-47 reduces Long-Term Potentiation and Postsynaptic Protein Levels in Mouse Hippocampus
    Environmental Health Perspectives, 2007
  6. Synapse-Associated Protein-97 Mediates  -Secretase ADAM10 Trafficking and Promotes Its Activity
    Journal of Neuroscience, vol. 27, no. 7, pp. 1682–1691, 2007
  7. Combined Biomarkers for Early Alzheimer Disease Diagnosis
    Current Medicinal Chemistry, vol. 14, no. 11, pp. 1171–1178, 2007
  8. A Critical Interaction between NR2B and MAGUK in L-DOPA Induced Dyskinesia
    Journal of Neuroscience, vol. 26, no. 11, pp. 2914–2922, 2006
  9. Calcium?calmodulin-dependent protein kinase?II phosphorylation modulates PSD-95 binding to NMDA receptors
    European Journal of Neuroscience, vol. 24, no. 10, pp. 2694–2704, 2006
  10. NR2B Subunit Exerts a Critical Role in Postischemic Synaptic Plasticity
    Stroke, vol. 37, no. 7, pp. 1895–1901, 2006
  11. BMC Neuroscience, vol. 7, no. 1, p. 71, 2006
  12. BMC Neurology, vol. 6, no. 1, p. 31, 2006
  13. Interleukin-1beta Released by gp120 Drives Neural Death through Tyrosine Phosphorylation and Trafficking of NMDA Receptors
    Journal of Biological Chemistry, vol. 281, no. 40, pp. 30212–30222, 2006
  14. NMDA Receptor Composition Differs Among Anatomically Diverse Malformations of Cortical Development
    Journal of Neuropathology and Experimental Neurology, vol. 65, no. 9, pp. 883–893, 2006
  15. Catechol-o-methyltransferase gene polymorphism in dementia with Lewy bodies-related psychosis: evidence for a genetic predisposition
    International Psychogeriatrics, vol. 18, no. 04, p. 755, 2006
  16. Tau haplotype affects CSF Tau levels in frontotemporal dementia
    Journal of Neurology, vol. 253, no. 7, pp. 946–946, 2006
  17. Preface
    European Journal of Pharmacology, vol. 545, no. 1, pp. 1–1, 2006
  18. New targets for pharmacological intervention in the glutamatergic synapse
    European Journal of Pharmacology, vol. 545, no. 1, pp. 2–10, 2006
  19. Predicting Alzheimer dementia in mild cognitive impairment patientsAre biomarkers useful?
    European Journal of Pharmacology, vol. 545, no. 1, pp. 73–80, 2006
  20. Combined Tc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD
    Neurobiology of Aging, vol. 27, no. 1, pp. 24–31, 2006
  21. Genetic correlates of behavioral endophenotypes in Alzheimer disease: Role of COMT, 5-HTTLPR and APOE polymorphisms
    Neurobiology of Aging, vol. 27, no. 11, pp. 1595–1603, 2006
  22. Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients
    Journal of the Neurological Sciences, vol. 229-230, pp. 211–213, 2005
  23. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients
    Neurobiology of Disease, vol. 19, no. 1-2, pp. 237–242, 2005
  24. Pre–clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis
    Journal of Neurology, vol. 252, no. 11, pp. 1359–1362, 2005
  25. Journal of Translational Medicine, vol. 3, no. 1, p. 30, 2005
  26. Management of Glaucoma: Focus on Pharmacological Therapy
    Drugs & Aging, vol. 22, no. 1, pp. 1–21, 2005
  27. Abnormal Ca2+-Calmodulin-Dependent Protein Kinase II Function Mediates Synaptic and Motor Deficits in Experimental Parkinsonism
    Journal of Neuroscience, vol. 24, no. 23, pp. 5283–5291, 2004
  28. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines
    Journal of Neurochemistry, vol. 90, no. 6, pp. 1489–1499, 2004
  29. Predicting Cognitive Decline in Alzheimer Disease
    Alzheimer Disease & Associated Disorders, vol. 18, no. 1, pp. 32–34, 2004
  30. Calcium/Calmodulin-dependent Protein Kinase II Phosphorylation Drives Synapse-associated Protein 97 into Spines
    Journal of Biological Chemistry, vol. 279, no. 22, pp. 23813–23821, 2004
  31. Cognitive and neurological deficits induced by early and prolonged basal forebrain cholinergic hypofunction in rats
    Experimental Neurology, vol. 189, no. 1, pp. 162–172, 2004
  32. Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators
    Neurobiology of Aging, vol. 25, no. 6, pp. 747–751, 2004
  33. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts
    Neurobiology of Disease, vol. 16, no. 2, pp. 454–460, 2004
  34. Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease
    Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 28, no. 5, pp. 763–770, 2004
  35. Platelet Amyloid Precursor Protein Abnormalities in Mild Cognitive Impairment Predict Conversion to Dementia of Alzheimer Type: A 2-Year Follow-up Study
    Archives of Neurology, vol. 60, no. 12, pp. 1740–1744, 2003
  36. Neurogenesis in Cerebral Heterotopia Induced in Rats by Prenatal Methylazoxymethanol Treatment
    Cerebral Cortex, vol. 13, no. 7, pp. 736–748, 2003
  37. Regulation of Dopamine D1 Receptor Trafficking and Desensitization by Oligomerization with Glutamate N-Methyl-D-aspartate Receptors
    Journal of Biological Chemistry, vol. 278, no. 22, pp. 20196–20202, 2003
  38. CaMKII-dependent Phosphorylation Regulates SAP97/NR2A Interaction
    Journal of Biological Chemistry, vol. 278, no. 45, pp. 44745–44752, 2003
  39. Biological markers in Alzheimer disease
    Neurobiology of Aging, vol. 24, no. 1, pp. 191–193, 2003
  40. High cholesterol affects platelet APP processing in controls and in AD patients
    Neurobiology of Aging, vol. 24, no. 5, pp. 631–636, 2003
  41. Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease
    Neuroscience Letters, 2003
  42. Microvascular damage and platelet abnormalities in early Alzheimer's disease
    Journal of the Neurological Sciences, vol. 203-204, pp. 189–193, 2002
  43. euroSCIENCE moves into sixth gear!
    Trends in Neurosciences, vol. 25, no. 11, pp. 591–594, 2002
  44. Lack of PSD-95 drives hippocampal neuronal cell death through activation of an alphaCaMKII transduction pathway
    European Journal of Neuroscience, vol. 16, no. 5, pp. 777–786, 2002
  45. alphaCaMKII and NMDA-Receptor Subunit Expression in Epileptogenic Cortex from Human Periventricular Nodular Heterotopia
    Epilepsia, vol. 43, no. s5, pp. 209–216, 2002
  46. Effects of streptozotocin-diabetes on the hippocampal NMDA receptor complex in rats
    Journal of Neurochemistry, vol. 80, no. 3, pp. 438–447, 2002
  47. ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model
    European Neuropsychopharmacology, vol. 12, p. 0, 2002
  48. Alzheimer Disease & Associated Disorders, vol. 16, no. 3, pp. 150–155, 2002
  49. Abnormalities in the Pattern of Platelet Amyloid Precursor Protein Forms in Patients With Mild Cognitive Impairment and Alzheimer Disease
    Archives of Neurology, vol. 59, no. 1, pp. 71–75, 2002
  50. Early stages of probable Alzheimer disease are associated with changes in platelet amyloid precursor protein forms
    Neurological Sciences, vol. 23, no. 5, pp. 207–210, 2002
  51. Amyloid Precursor Protein in Platelets of Patients With Alzheimer Disease: Effect of Acetylcholinesterase Inhibitor Treatment
    Archives of Neurology, vol. 58, no. 3, pp. 442–446, 2001
  52. NMDA receptor subunits are phosphorylated by activation of neurotrophin receptors in PSD of rat spinal cord
    Neuroreport, vol. 12, no. 6, pp. 1301–1305, 2001
  53. Protein Kinase C Activation Modulates alpha -Calmodulin Kinase II Binding to NR2A Subunit of N-Methyl-D-Aspartate Receptor Complex
    Journal of Biological Chemistry, vol. 276, no. 10, pp. 7609–7613, 2001
  54. Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target
    Mechanisms of Ageing and Development, vol. 122, no. 16, pp. 1997–2004, 2001
  55. (+)-MCPG induces PKCepsilon translocation in cortical synaptosomes through a PLD-coupled mGluR
    European Journal of Neuroscience, vol. 12, no. 4, pp. 1310–1318, 2000
  56. Subcellular localization and axonal transport of the survival motor neuron (SMN) protein in the developing rat spinal cord
    Human Molecular Genetics, vol. 9, no. 1, pp. 47–56, 2000
  57. Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease: the case of amyloid precursor protein
    European Journal of Pharmacology, vol. 405, no. 1-3, pp. 277–283, 2000
  58. Pathophysiological implications of the structural organization of the excitatory synapse
    European Journal of Pharmacology, vol. 375, no. 1-3, pp. 339–347, 1999
  59. aCaMKII binding to the C-terminal tail of NMDA receptor subunit NR2A and its modulation by autophosphorylation
    FEBS Letters, vol. 456, no. 3, pp. 394–398, 1999
  60. Abnormalities of Amyloid beta Precursor Protein Expression in Platelets of Patients With Alzheimer Disease: Do We Understand Them Well Enough?
    Archives of Neurology, vol. 56, no. 7, pp. 889–891, 1999
  61. NMDA receptor subunits are modified transcriptionally and post-translationally in the brain of streptozotocin-diabetic rats
    Diabetologia, vol. 42, no. 6, pp. 693–701, 1999
  62. Differential Level of Platelet Amyloid beta Precursor Protein Isoforms: An Early Marker for Alzheimer Disease
    Archives of Neurology, vol. 55, no. 9, pp. 1195–1200, 1998
  63. Dysplastic neocortex and subcortical heterotopias in methylazoxymethanol-treated rats: an intracellular study of identified pyramidal neurones
    Neuroscience Letters, vol. 246, no. 3, pp. 181–185, 1998
  64. Altered connections between neocortical and heterotopic areas in methylazoxymethanol-treated rat
    Epilepsy Research, vol. 32, no. 1-2, pp. 49–62, 1998
  65. Increased Presynaptic Protein Kinase C Activity and Glutamate Release in Rats with a Prenatally Induced Hippocampal Lesion
    European Journal of Neuroscience, vol. 9, no. 3, pp. 472–479, 1997
  66. Determination of the endogenous phosphorylation state of B-50/GAP-43 and neurogranin in different brain regions by electrospray mass spectrometry
    FEBS Letters, vol. 389, no. 3, pp. 309–313, 1996
  67. Differential translocation of protein kinase C isozymes in rats characterized by a chronic lack of LTP induction and cognitive impairment
    FEBS Letters, vol. 393, no. 1, pp. 121–123, 1996
  68. Levels of NGF, p75NGFR and ChAT immunoreactivity in brain of adult and aged microencephalic rats
    Neurobiology of Aging, vol. 17, no. 1, pp. 137–142, 1996
  69. Selective in vitro blockade of neuroepithelial cells proliferation by methylazoxymethanol, a molecule capable of inducing long lasting functional impairments
    Journal of Neuroscience Research, vol. 41, no. 5, pp. 640–647, 1995
  70. Changes in Protein Kinase C and its Presynaptic Substrate B-SO/GAP-43 after Intrauterine Exposure to Methylazoxy-methanol, a Treatment Inducing Cortical and Hippocampal Damage and Cognitive Deficit in Rats
    European Journal of Neuroscience, vol. 7, no. 5, pp. 899–906, 1995
  71. Selective alteration in B-50/GAP-43 phosphorylation in brain areas of animals characterized by cognitive impairment
    Brain Research, vol. 607, no. 1-2, pp. 329–332, 1993
  72. The impaired long-term potentiation in the CA1 field of the hippocampus of cognitive deficient microencephalic rats is restored byd-serine
    Neuroscience, vol. 54, no. 1, pp. 49–60, 1993
  73. Measurement of relative amounts of phospho- and dephospho-B-50(GAP-43) peptides by fast atom bombardment-mass spectrometry
    FEBS Letters, vol. 301, no. 2, pp. 150–154, 1992
  74. ß-Adrenoceptor desensitization induced by antigen challenge in guinea-pig trachea
    European Journal of Pharmacology, vol. 178, no. 1, pp. 21–27, 1990
  75. In vivo modulation of striatal phosphoproteins by dopaminergic agents
    European Journal of Pharmacology: Molecular Pharmacology, vol. 172, no. 4-5, pp. 321–328, 1989
  76. Methylazoxymethanol-induced microencephaly: persistent increase of cortical somatostatin-like immunoreactivity
    Developmental Brain Research, vol. 47, no. 1, pp. 156–159, 1989
  77. Evidence for multiple transduction mechanisms of dopamine D-2 receptors
    Pharmacological Research Communications, vol. 19, no. 12, pp. 949–950, 1987
  78. Adenosine modulates the dopaminergic function in the nigro-striatal system by interacting with striatal dopamine dependent adenylate cyclase
    Pharmacological Research Communications, vol. 19, no. 4, pp. 275–286, 1987